Wee Joo Chng Selected Research

Necrosis

1/2018	Neutrophils differentially attenuate immune response to Aspergillus infection through complement receptor 3 and induction of myeloperoxidase.
4/2014	CD137 ligand signalling induces differentiation of primary acute myeloid leukaemia cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wee Joo Chng Research Topics

Disease

53	Neoplasms (Cancer) 01/2024 - 07/2010
47	Multiple Myeloma 01/2024 - 04/2005
9	Lymphoma (Lymphomas) 01/2024 - 03/2012
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023 - 01/2011
7	Neoplasm Metastasis (Metastasis) 01/2023 - 07/2010
5	Infections 01/2023 - 11/2012
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2023 - 03/2012
4	Hematologic Neoplasms (Hematological Malignancy) 11/2022 - 01/2018
4	Carcinogenesis 01/2019 - 02/2010
3	COVID-19 01/2023 - 10/2020
3	Paraproteinemias (Monoclonal Gammopathy) 01/2022 - 02/2008
3	Hypoxia (Hypoxemia) 01/2021 - 01/2016
3	Residual Neoplasm 01/2021 - 01/2017
3	Leukemia 01/2021 - 11/2016
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 12/2016
2	Monoclonal Gammopathy of Undetermined Significance 01/2022 - 01/2022
2	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 01/2021
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021 - 01/2014
2	Febrile Neutropenia 09/2018 - 11/2012
2	Necrosis 01/2018 - 04/2014
2	Breast Neoplasms (Breast Cancer) 01/2017 - 01/2016
1	Blast Crisis (Blast Phase) 01/2023
1	Amyloidosis 01/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2022
1	Colonic Neoplasms (Colon Cancer) 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 10/2023 - 07/2010
8	RNA (Ribonucleic Acid)IBA 10/2023 - 01/2018
7	Bortezomib (Velcade)FDA Link 01/2020 - 09/2013
6	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2023 - 07/2010
6	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2018
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2024 - 09/2015
5	daratumumabIBA 10/2023 - 01/2021
5	Messenger RNA (mRNA)IBA 01/2023 - 02/2008
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2013
5	Oncogene Proteins (Oncogene Protein)IBA 11/2021 - 02/2012
5	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 09/2005
4	Lenalidomide (CC 5013)FDA Link 10/2023 - 09/2015
4	AntibodiesIBA 10/2023 - 02/2012
4	Tyrosine Kinase InhibitorsIBA 01/2023 - 03/2012
4	ChromatinIBA 01/2022 - 12/2016
4	MicroRNAs (MicroRNA)IBA 11/2016 - 10/2011
3	carfilzomibIBA 01/2024 - 01/2019
3	Histone MethyltransferasesIBA 10/2023 - 08/2012
3	Zoledronic Acid (Zometa)FDA Link 01/2022 - 01/2018
3	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 01/2014
3	Interleukin-6 (Interleukin 6)IBA 01/2020 - 12/2012
3	Proteasome InhibitorsIBA 10/2019 - 09/2015
3	CytokinesIBA 01/2018 - 12/2012
2	mRNA VaccinesIBA 01/2023 - 01/2023
2	VaccinesIBA 01/2023 - 11/2014
2	Oxygen (Dioxygen)IBA 01/2023 - 01/2021
2	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2022 - 01/2022
2	ParaproteinsIBA 01/2022 - 01/2018
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 01/2015
2	Histones (Histone)IBA 01/2022 - 01/2017
2	HydrolasesIBA 10/2020 - 01/2011
2	AntigensIBA 10/2020 - 01/2019
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 07/2015
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2019 - 12/2018
2	Drug CombinationsIBA 01/2019 - 01/2018
2	Carbapenems (Carbapenem Antibiotics)IBA 09/2018 - 11/2012
2	VS-5584IBA 11/2017 - 02/2013
2	Telomerase (Telomerase Reverse Transcriptase)IBA 12/2016 - 12/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 06/2014 - 11/2012
2	ErbB Receptors (EGF Receptor)IBA 02/2013 - 03/2012
2	Phosphotransferases (Kinase)IBA 02/2013 - 03/2012
1	Thalidomide (Thalomid)FDA Link 01/2024
1	HexokinaseIBA 10/2023
1	Complement Inactivating AgentsIBA 10/2023
1	isatuximabIBA 10/2023
1	Small Cytoplasmic RNAIBA 01/2023
1	Inosine FDA Link 01/2023
1	Adenosine (Adenocard)FDA LinkGeneric 01/2023
1	Imatinib Mesylate (Gleevec)FDA Link 01/2023
1	Immunoglobulin D (IgD)IBA 01/2023
1	Exonucleases (3' 5' Exonuclease)IBA 01/2023
1	EnzymesIBA 01/2023
1	Core Binding Factors (Core-Binding Factor)IBA 01/2023
1	3' Untranslated Regions (3' UTR)IBA 01/2022
1	Histone-Lysine N-MethyltransferaseIBA 01/2022
1	B-Cell Maturation AntigenIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	piperidineIBA 01/2022
1	Lysine (L-Lysine)FDA Link 01/2022
1	Immunoglobulin M (IgM)IBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	ZAP-70 Protein-Tyrosine Kinase (ZAP 70 Protein Tyrosine Kinase)IBA 01/2022
1	PronaseIBA 01/2022
1	Histone ChaperonesIBA 01/2022
1	ParaffinIBA 01/2022
1	ibrutinibIBA 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 12/2021

Therapy/Procedure

35	Therapeutics 01/2024 - 04/2005
8	Immunotherapy 01/2024 - 01/2014
7	Drug Therapy (Chemotherapy) 01/2023 - 08/2012
1	Critical Care (Surgical Intensive Care) 01/2023
1	Intravenous Injections 01/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022